John Plankeel, MD
Pulmonary Disease · Lynchburg, VANPI 1538197744
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. United Therapeutics Corporation accounts for 81.3% of it on its own, with 27 other manufacturers making up the rest. Reporting peaked in 2019 at $21,073 and has fallen 99.3% since, to $143 in 2025. Among pulmonary disease clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $271.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$49K
- Merck$7K
- Inspire Medical Systems, Inc.$1K
- GSK$393
- Actelion Pharmaceuticals US, Inc.$382
- AstraZeneca$375
- plus $2K from 22 others
What the payments were for
- Consulting fees$11,58519%
- Speaking & faculty fees$36,14859%
- Travel & lodging$7,60813%
- Food & beverage$4,9848%
- Education$4391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 91 | $49,400 |
| Merck | 15 | $7,136 |
| Inspire Medical Systems, Inc. | 11 | $1,398 |
| GSK | 25 | $393 |
| Actelion Pharmaceuticals US, Inc. | 11 | $382 |
| AstraZeneca | 21 | $375 |
| Harmony Biosciences LLC | 6 | $245 |
| Sanofi | 9 | $230 |
| Amgen | 7 | $199 |
| Galvanize Therapeutics, Inc | 1 | $143 |
| ZOLL Respicardia, Inc. | 1 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $109 |
| Abbott | 1 | $98 |
| Regeneron Healthcare Solutions, Inc. | 1 | $96 |
| Boehringer Ingelheim | 3 | $95 |
| Philips North America LLC | 4 | $80 |
| Mallinckrodt Hospital Products Inc. | 1 | $37 |
| Bayer | 1 | $22 |
| Novartis | 1 | $20 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Resmed Corp | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $17 |
| Grifols USA, LLC | 1 | $16 |
| Sandoz | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENITRAM$32,463
- TYVASO$20,741
- REMODULIN$15,615
- Inspire$1,089
- ALIYA SYSTEM$143
- remede System$142
How this compares
$60,763 in reported general payments places this provider in the 90th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 109 | $1,351,887 |
| UptraviSelexipag | 41 | $1,092,780 |
| Orenitram ErTreprostinil Diolamine | 31 | $463,276 |
| AdempasRiociguat | 29 | $396,795 |
| Ambrisentan | 150 | $266,861 |
| Tyvaso DpiTreprostinil | 11 | $265,039 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 274 | $225,436 |
| RemodulinTreprostinil Sodium | 13 | $155,346 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 132 | $85,148 |
| EliquisApixaban | 87 | $77,191 |
| Spiriva RespimatTiotropium Bromide | 63 | $44,029 |
| Breo ElliptaFluticasone/Vilanterol | 68 | $43,662 |
| Pirfenidone | 20 | $33,043 |
| Sildenafil Citrate | 137 | $30,290 |
| Tadalafil | 66 | $27,334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $382 | $2,444,667150 claims |
| BayerAdempas | $22 | $396,79529 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $393 | $362,823490 claims |
| United Therapeutics CorporationRemodulin | $49,400 | $155,34613 claims |
| PfizerEliquis | $20 | $77,19187 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $95 | $61,53186 claims |
| AstraZenecaSymbicort, Breztri Aerosphere, Bevespi Aerosphere | $375 | $27,84980 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Lynchburg
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
- Eric LibreAnnandale$302K
- Sujoy GillRichmond$296K
- Imre NothCharlottesville$256K
- Carlos SilvaChesapeake$245K
- Vijay SubramaniamWilliamsburg$228K
- Ellen VolkerCharlottesville$177K
- Himanshu DesaiChesapeake$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.